Recent studies have investigated the use of newer oral antifungal agents including terbinafine, fluconazole, and itraconazole in the treatment of tinea capitis. Potential advantages over griseofulvin include improved efficacy as well as a shorter treatment course with associated cost savings and improved compliance. There is no currently approved treatment for tinea capitis in childhood in the UK apart from griseofulvin. However, there are a number of options. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized.
Griseofulvin taken for 6 to 8 weeks remains an effective therapy for tinea capitis. There are insufficient randomized controlled trials directly comparing these. Gris-PEG® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis.
Griseofulvin is still considered to be the treatment of choice for tinea capitis.3,4 The absence of pivotal clinical trials comparing griseofulvin with newer.